60 related articles for article (PubMed ID: 16472706)
1. Optimizing therapy in previously treated non-small cell lung cancer.
Miller VA
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S25-31. PubMed ID: 16472706
[TBL] [Abstract][Full Text] [Related]
2. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
3. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
4. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
5. Use of novel second-line targeted therapies in non-small cell lung cancer.
Massarelli E; Herbst RS
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
[TBL] [Abstract][Full Text] [Related]
6. Second-line treatment options in advanced non-small cell lung cancer: current status.
Cullen M
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S3-8. PubMed ID: 16472703
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
[TBL] [Abstract][Full Text] [Related]
8. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
Burris HA
Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
Johnson DH
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4451s-4457s. PubMed ID: 16857827
[TBL] [Abstract][Full Text] [Related]
10. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
11. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
12. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
[TBL] [Abstract][Full Text] [Related]
16. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?
Saijo N
Nat Clin Pract Oncol; 2005 Jun; 2(6):275. PubMed ID: 16264964
[No Abstract] [Full Text] [Related]
17. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy in lung carcinoma].
Egger T; Cerny T
Ther Umsch; 1994 Apr; 51(4):267-71. PubMed ID: 7514814
[TBL] [Abstract][Full Text] [Related]
19. [Second-line chemotherapy in non-small-cell lung cancer].
Schütte W
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S13-4S16. PubMed ID: 15687987
[No Abstract] [Full Text] [Related]
20. Second-line for small cell lung cancer: how-to-do-it?
Postmus PE
Lung Cancer; 2005 May; 48(2):263-5. PubMed ID: 15829327
[No Abstract] [Full Text] [Related]
[Next] [New Search]